Lennham Pharmaceuticals Announces Issuance of U.S. Patent Covering Deuterated Psilocybin Products

Lennham Pharmaceuticals, a clinical-stage start-up focused on the creative use of deuterium chemistry to improve the metabolic and pharmacological profile of existing compounds, announced that the United States Patent & Trademark Office (USPTO) issued U.S. Patent No. 11,000,534 with an expiration date of December 2040. This patent broadly covers pharmaceutical compositions comprising deuterated forms of psilocybin.

“Psilocybin has shown incredible promise in recent clinical studies as a potential treatment for major depressive disorder and other psychiatric diseases and disorders,” said Bradford C. Sippy, Founder and CEO of Lennham. “However, because psilocybin is a naturally occurring and extensively studied compound, it is unlikely that meaningful patent protection can be obtained on psilocybin or any products incorporating psilocybin. The issuance of this patent positions Lennham to have the most significant patent coverage for any psilocybin-based product in development. We intend to rapidly advance our differentiated product through the 505(b)(2) approval pathway by leveraging the existing known data on psilocybin.”

The issued patent is entitled “Deuterated Derivatives of Psilocybin and Uses Thereof”. The issued claims are directed to pharmaceutical compositions comprising two forms of deuterium-enriched psilocybin.